产品
编 号：F252486
产品类型
规格
价格
是否有货
结构图
CAS No: 2055491-00-2
产品详情
生物活性：
Tagraxofusp (SL-401) is a potent IL-3 receptor inhibitor to inhibits plasmacytoid dendritic cells (pDCs) growth in multiple myeloma (MM) bone marrow (BM) microenvironment. Tagraxofusp has synergistic effect with Bortezomib (HY-10227) and Pomalidomide (HY-10984) to suppress multiple myeloma (MM).
体内研究：
Tagraxofusp (12-50 μg/kg; 静脉注射; 每周 5 次, 共 3 周) 阻断 pDC 诱导的肿瘤生长，延长带有皮下INA-6 多发性骨髓瘤的 SCID-hu 小鼠的生存期。 Tagraxofusp (16 μg/kg; i.v.; 静脉注射; 每周 5 次, 共 1 周) 可增强 2.5 mg/kg Pomalidomide 在皮下多发性骨髓瘤 CB-17 小鼠中的抗多发性骨髓瘤活性。Animal Model:SCID-hu mice with INA-6 MM cells
Dosage:12 μg/kg, 16 μg/kg, 25 μg/kg and 50 μg/kg
Administration:Intravenous injection; for 5 consecutive days each week for 3 weeks
Result:Blocked pDC-induced tumor growth and prolonged mice survival at 12 μg/kg.Showed well tolerance at 16 μg/kg, while higher doses resulted in body weight decrease and toxicity.
Animal Model:CB-17 mice with subcutaneous MM xenograft model
Dosage:16 μg/kg; with or without 2.5 mg/kg Pomalidomide (p.o.; 4 consecutive days weekly for 2 weeks)
Administration:Intravenous injection; dose at 5 consecutive days for first week
Result:Enhanced the anti-MM activity of proteasome inhibitor and immunomodulatory drug pomalidomide.
体外研究：
Tagraxofusp (0-1367 pM; 72 小时) 抑制 pDCs的活力，以及pDCs诱导的MM细胞增殖。Tagraxofusp (0-136.7 pM; 2-3 周) 抑制破骨细胞形成和骨吸收，以及稳定成骨细胞形成。Tagraxofusp (0-13.67 nM; 48 小时)在 MM 中靶向肿瘤启动干细胞样细胞。
Tagraxofusp (SL-401) is a potent IL-3 receptor inhibitor to inhibits plasmacytoid dendritic cells (pDCs) growth in multiple myeloma (MM) bone marrow (BM) microenvironment. Tagraxofusp has synergistic effect with Bortezomib (HY-10227) and Pomalidomide (HY-10984) to suppress multiple myeloma (MM).
体内研究：
Tagraxofusp (12-50 μg/kg; 静脉注射; 每周 5 次, 共 3 周) 阻断 pDC 诱导的肿瘤生长，延长带有皮下INA-6 多发性骨髓瘤的 SCID-hu 小鼠的生存期。 Tagraxofusp (16 μg/kg; i.v.; 静脉注射; 每周 5 次, 共 1 周) 可增强 2.5 mg/kg Pomalidomide 在皮下多发性骨髓瘤 CB-17 小鼠中的抗多发性骨髓瘤活性。Animal Model:SCID-hu mice with INA-6 MM cells
Dosage:12 μg/kg, 16 μg/kg, 25 μg/kg and 50 μg/kg
Administration:Intravenous injection; for 5 consecutive days each week for 3 weeks
Result:Blocked pDC-induced tumor growth and prolonged mice survival at 12 μg/kg.Showed well tolerance at 16 μg/kg, while higher doses resulted in body weight decrease and toxicity.
Animal Model:CB-17 mice with subcutaneous MM xenograft model
Dosage:16 μg/kg; with or without 2.5 mg/kg Pomalidomide (p.o.; 4 consecutive days weekly for 2 weeks)
Administration:Intravenous injection; dose at 5 consecutive days for first week
Result:Enhanced the anti-MM activity of proteasome inhibitor and immunomodulatory drug pomalidomide.
体外研究：
Tagraxofusp (0-1367 pM; 72 小时) 抑制 pDCs的活力，以及pDCs诱导的MM细胞增殖。Tagraxofusp (0-136.7 pM; 2-3 周) 抑制破骨细胞形成和骨吸收，以及稳定成骨细胞形成。Tagraxofusp (0-13.67 nM; 48 小时)在 MM 中靶向肿瘤启动干细胞样细胞。
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备